<Date>
<Prescriber Name>
<Address >
<Address>

Dear <Prescriber Name>,

On May 10, 2016 the U.S. Food and Drug Administration (FDA) issued a safety alert to health care professionals regarding a rare but serious skin reaction known as Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) that can occur with the use of Olanzapine. Olanzapine is available under the brand names Zyprexa, Zyprexa Zydis, Zyprexa Relprevv, and Symbyax, and also as generics.

Health care professionals should immediately stop treatment with olanzapine if DRESS is suspected. There is currently no specific treatment for DRESS. The important ways to manage DRESS are early recognition of the syndrome, discontinuation of the offending agent as soon as possible, and supportive care. When prescribing the medicine, explain the signs and symptoms of severe skin reactions to your patients and tell them when to seek immediate medical care.

Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA's MedWatch Safety Information and Adverse Event Reporting Program:

- Complete and submit the report Online: www.fda.gov/MedWatch/report
- Download form, or call 800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 800-FDA-0178

If you have any questions or concerns about US Script's response to the product recall, please contact Iris Ivey, Drug Utilization Review Clinical Pharmacist, at 800-225-2573, ext. 82376, iivey@usscript.com, or contact Jill Erkens, Manager DUR/Clinical Services, at 314-202-1148, jerkens@usscript.com.

Best Regards,

Cenpatico Provider Relations